» Articles » PMID: 21906871

Disruption of XCT Inhibits Cell Growth Via the ROS/autophagy Pathway in Hepatocellular Carcinoma

Overview
Journal Cancer Lett
Specialty Oncology
Date 2011 Sep 13
PMID 21906871
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

xCT, the functional subunit of the system x(c)(-) which plays an important role in maintaining intracellular glutathione (GSH) levels, is expressed in various malignant tumors. Here, we demonstrated that xCT expression is often elevated in HCC and is associated with poor prognosis in HCC patients; moreover, disruption of xCT suppressed HCC cell growth both in vitro and in vivo. xCT dysfunction has also been shown to increase intracellular reactive oxygen species (ROS) levels, thus in turn led to autophagic cell death of HCC cells. Taken together, these findings suggest that xCT may be a promising therapeutic target for human HCC.

Citing Articles

Hepatic Iron Overload and Hepatocellular Carcinoma: New Insights into Pathophysiological Mechanisms and Therapeutic Approaches.

Chatzikalil E, Arvanitakis K, Kalopitas G, Florentin M, Germanidis G, Koufakis T Cancers (Basel). 2025; 17(3).

PMID: 39941760 PMC: 11815926. DOI: 10.3390/cancers17030392.


Glutathione: A Key Regulator of Extracellular Matrix and Cell Death in Intervertebral Disc Degeneration.

Li F, Li S, Shi Y, Lin F, Rui L, Shi J Mediators Inflamm. 2024; 2024:4482642.

PMID: 39403548 PMC: 11473174. DOI: 10.1155/2024/4482642.


Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics.

Li T, Song Y, Wei L, Song X, Duan R Cell Commun Signal. 2024; 22(1):491.

PMID: 39394612 PMC: 11470700. DOI: 10.1186/s12964-024-01871-9.


Effects on Iron Metabolism and System Xc- /GPX4 Pathway from Hydroquinone Suggest Ferroptosis of Jurkat Cells.

Liu N, Liu G, Li Q, Hu Y, Wang H Toxics. 2024; 12(9).

PMID: 39330572 PMC: 11436165. DOI: 10.3390/toxics12090644.


Zinc finger domain of p62/SQSTM1 is involved in the necroptosis of human cisplatin‑resistant ovarian cancer cells treated with sulfasalazine.

Liu N, Liu S, Zhang X, Tian W, Jia H, Ye X Oncol Lett. 2024; 28(5):529.

PMID: 39290957 PMC: 11406577. DOI: 10.3892/ol.2024.14662.